Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Cottin, M. Reynaud-Gaubert, J. Traclet, D. Montani, H. Nunes, B. Wallaert, B. Camara, C. Khouatra, D. Launay, S. Marchand-Adam, D. Israel-Biet, R. Magnier, L. Tétu, S. Zeghmar, L. Kiakouama, M. Humbert, J.F. Cordier (Lyon, Marseille, Clamart, Bobigny, Lille, Grenoble, Tours, Paris, Caen, Toulouse, France). Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study. Eur Respir J 2012; 40: Suppl. 56, 3273

Member's Comments

No comment yet.

Related content which might interest you: Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017 Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study Source: Eur Respir J 2007; 30: Suppl. 51, 119s Year: 2007 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021 Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 The association of diuretics treatment with hospitalization rates of patients with chronic obstructive pulmonary disease and pulmonary hypertension: a population-based study Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Ergospirometry findings in patients with scleroderma in relation to concurrent pulmonary hypertension Source: Annual Congress 2010 - Exercise in healthy and non-respiratory diseases Year: 2010 Longitudinal change in non-invasive markers in interstitial lung disease associated pulmonary hypertension and correlation with invasive pulmonary haemodynamics Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Everolimus improves exercise capacity and pulmonary vascular resistance in patients with advanced pulmonary hypertension – A pilot study Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study Source: Eur Respir J, 54 (4) 1900897; 10.1183/13993003.00897-2019 Year: 2019 Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study Source: Eur Respir J, 53 (3) 1802093; 10.1183/13993003.02093-2018 Year: 2019 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010